Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Schwab US Dividend Equity ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Schwab US Dividend Equity ETF trades at $33.86 (market cap $111.61B). The key difference: Schwab US Dividend Equity ETF is far larger — about 114.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Schwab US Dividend Equity ETF is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Schwab US Dividend Equity ETF for 64 Days on average.
| MRVI | SCHD | |
|---|---|---|
Market Cap | $972.90M | $111.61B |
Volume | 4,325,710 | 22,238,193 |
Sector | Health | Broad Market / Factor |
52-Week High | $9.00 | $35.21 |
52-Week Low | $2.83 | $26.44 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
SCHD trades at $33.37, up 0.33% with a bullish technical signal from moving averages. Recent news highlights SCHD outperforming the S&P 500 in 2026 and growing its dividend. The ETF's defensive dividend strategy faces scrutiny after missing gains from stocks like Broadcom due to its selection rules.
The outlook remains positive for income investors seeking quality dividend growth with lower risk through diversification. Key risks include interest rate sensitivity and the opportunity cost of excluded high-growth stocks. Current technical strength supports near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
